Portal hemodynamic effects of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma: a prospective cohort study
Latest Information Update: 19 Feb 2021
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics
- 19 Feb 2021 New trial record